Comparative Pharmacology
Head-to-head clinical analysis: BILTRICIDE versus HETRAZAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BILTRICIDE versus HETRAZAN.
BILTRICIDE vs HETRAZAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Category C
Category C
Anthelmintic
Anthelmintic